RxDoctor Payments Data

Anitha Bhat, MD

Internal Medicine · Apple Valley, CANPI 1639480585

Payments from drug & device makers

$1,492in general payments, 2019–2025

Across 82 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$266
  • Lilly USA, LLC$224
  • Boehringer Ingelheim$112
  • Pfizer$105
  • Bayer$103
  • AstraZeneca$93
  • plus $589 from 16 others

What the payments were for

  • Food & beverage$1,46798%
  • Education$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,492 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$93,940
Medicare patients
187
Services billed
977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$88,592
JardianceEmpagliflozin91$85,350
EliquisApixaban85$84,969
CreonLipase/Protease/Amylase26$41,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$33,505
JanuviaSitagliptin Phosphate25$20,933
XareltoRivaroxaban22$19,855
MounjaroTirzepatide12$18,225
TrulicityDulaglutide13$12,468
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen473$11,137
KerendiaFinerenone12$7,926
Combivent RespimatIpratropium/Albuterol Sulfate14$6,739
Levothyroxine Sodium405$5,275
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$5,099
Albuterol Sulfate HfaAlbuterol Sulfate192$4,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$112$92,090105 claims
PfizerEliquis$105$84,96985 claims
AbbVieCreon$19$41,16826 claims
GSKTrelegy Ellipta$59$33,50545 claims
Lilly USA, LLCMounjaro, Trulicity$224$30,69325 claims
MerckJanuvia$61$20,93325 claims
Johnson & JohnsonXarelto$31$19,85522 claims
BayerKerendia$103$7,92612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →